Question to the Department of Health and Social Care:

To ask His Majesty's Government how many yellow card reports of anti-androgen withdrawal syndrome the Medicines and Healthcare products Regulatory Agency has received each year since 2010; and what medications those reports were tied to.

The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for ensuring medicines, medical devices, and blood components for transfusion meet applicable standards of safety, quality, and efficacy. The MHRA rigorously assesses available data, including from the Yellow Card scheme, and seeks advice from the Commission on Human Medicines, the MHRA’s independent advisory committee, where appropriate, to inform regulatory decisions including amending the product information.

Up to and including 1 July 2026 the MHRA has not received any Yellow Card reports which include anti-androgen withdrawal syndrome as a suspected adverse reaction.

Reporters are asked to submit Yellow Card reports even if they only have a suspicion that the medicine or vaccine may have caused the adverse reaction. A list of the recognised suspected adverse reactions is provided in the information for healthcare professionals and the recipient information, with further information available on the GOV.UK website.